Next Article in Journal
NMDA Receptor Modulators in the Treatment of Drug Addiction
Next Article in Special Issue
RNAi Therapeutics in Autoimmune Disease
Previous Article in Journal
Elucidating the Function of Penetratin and a Static Magnetic Field in Cellular Uptake of Magnetic Nanoparticles
Previous Article in Special Issue
siRNA Genome Screening Approaches to Therapeutic Drug Repositioning
Review

RNAi Therapeutic Platforms for Lung Diseases

1
Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, 104-0045, Japan
2
Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, 105-8461, Japan
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2013, 6(2), 223-250; https://doi.org/10.3390/ph6020223
Received: 19 December 2012 / Revised: 19 January 2013 / Accepted: 1 February 2013 / Published: 6 February 2013
(This article belongs to the Special Issue RNAi-Based Therapeutics)
RNA interference (RNAi) is rapidly becoming an important method for analyzing gene functions in many eukaryotes and holds promise for the development of therapeutic gene silencing. The induction of RNAi relies on small silencing RNAs, which affect specific messenger RNA (mRNA) degradation. Two types of small RNA molecules, i.e. small interfering RNAs (siRNAs) and microRNAs (miRNAs), are central to RNAi. Drug discovery studies and novel treatments of siRNAs are currently targeting a wide range of diseases, including various viral infections and cancers. Lung diseases in general are attractive targets for siRNA therapeutics because of their lethality and prevalence. In addition, the lung is anatomically accessible to therapeutic agents via the intrapulmonary route. Recently, increasing evidence indicates that miRNAs play an important role in lung abnormalities, such as inflammation and oncogenesis. Therefore, miRNAs are being targeted for therapeutic purposes. In this review, we present strategies for RNAi delivery and discuss the current state-of-the-art RNAi-based therapeutics for various lung diseases. View Full-Text
Keywords: RNAi; siRNA; miRNA; drug delivery system; lung diseases; lung cancer RNAi; siRNA; miRNA; drug delivery system; lung diseases; lung cancer
Show Figures

Figure 1

MDPI and ACS Style

Fujita, Y.; Takeshita, F.; Kuwano, K.; Ochiya, T. RNAi Therapeutic Platforms for Lung Diseases. Pharmaceuticals 2013, 6, 223-250. https://doi.org/10.3390/ph6020223

AMA Style

Fujita Y, Takeshita F, Kuwano K, Ochiya T. RNAi Therapeutic Platforms for Lung Diseases. Pharmaceuticals. 2013; 6(2):223-250. https://doi.org/10.3390/ph6020223

Chicago/Turabian Style

Fujita, Yu, Fumitaka Takeshita, Kazuyoshi Kuwano, and Takahiro Ochiya. 2013. "RNAi Therapeutic Platforms for Lung Diseases" Pharmaceuticals 6, no. 2: 223-250. https://doi.org/10.3390/ph6020223

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop